Investor Presentaiton
Strong Commitment to Environmental Protection and ESG
Sustainability Technologies
Ongoing investments into Green Technology Platforms
Bio-catalysis
☐
Continuous Flow Chemistry
Sustainability Management across All Sites
■
■
■
Carbon Emission Intensity (FY23 vs. 22 per Revenue): 16%^
Water Intensity (FY23 vs. 22 per Revenue): [14%
4% Energy from Renewable sources
77% of hazardous waste recycled / co-processed
Other initiatives: Swapped fuel-based vehicles with E-vehicles,
Installed VFDs across sites to regulate energy consumption etc
Well recognised from
Global agencies on
ESG score
MSCI
ESG RATINGS
CCC B
BBB
A AA AAA
Consecutive "BBB" rated by MSCI
ESG Ratings in FY22 & 23
Accreditation & Progress
☐
■
☐
Recognition from external ESG rating Agencies including MSCI, S&P
Dow Jones Sustainability Index (DJSI), CRISIL, and EcoVadis
Launched "SANKALP" to Enhance Organizational Safety Excellence
Won Several Awards on EHS best and innovative practices
Initiated new system certification ISO 50001:2018 across company
Double materiality assessment introduced (aligned with GRI, SASB)
to create greater impact
FY 2023 Integrated report published
Gain more insight on our enhanced sustainability strategy and commitments
SILVER
2022
ecovadis
Sustainability
Rating
Laurus Labs Limited
Pharmaceuticals
S&P Global ESG Score 2022
43/100
As of October 21, 2022
Scores are industry specific
Learn more at spglobal.com/esa/scores
S&P Global
Sustainable 1
Score improved by 30 points to
43/100 vs LY
Moved to Top quartile
for the first time in Dec-
22 review
68
CSRHUBⓇ
ESG Ranking (%)
Compared With
32,568 Companies
Low 0-29
30-39
40-49
50-59
60-79
80-100
High
27
^ Scope 1,2 and 3
Laurus Q2 & H1 FY 2024 Investor Presentation | October 20, 2023
LAURUS Labs
Knowledge. Innovation. ExcellenceView entire presentation